



Updated Monthly

December 9, 2025

Prepared for:



THE ESSENTIAL GUIDE TO

Non-Dilutive Government Funding

Published by:



Questions?

Liz Powell, Esq., MPH

lpowell@G2Gconsulting.com

www.G2Gconsulting.com

  @G2Gconsulting





GBG Report

Updated Monthly

December 9, 2025

<https://www.g2gconsulting.com/gbg-reporting-service/>

TABLE OF CONTENTS

New Opportunities

Aging.....	2
Artificial Intelligence & Machine Learning	3
Autoimmune Diseases	4
Biomedical Research.....	4
Biotechnology and Biomanufacturing.....	5
Cancer	5
Endocrine & Metabolic Disease	6
Food Allergies	7
Genomics	8
HIV/AIDS	8
Immunology & Infectious Disease	9
Maternal and Pediatric Health	10
Patient-Centered Research	10
Regulatory Science	10
Therapeutics.....	11
Women's Health.....	11

Recurring Opportunities

Advanced Research Projects Agency for Health	12
Air Force	13
Army.....	14
BARDA	16
DARPA	16
Defense Threat Reduction Agency	17
Department of Energy	18
Navy	18
Patient-Centered Outcomes Research Institute	19

GBG Acronyms	21
---------------------------	-----------



December 18, 2025 – Join us for G2G’s Monthly [Non-Dilutive Funding: GBG Reporting Service Webinar](#) at 12-12:30pm EST (FREE to all) and 12:30-1:00pm (premium service private consultation for G2G and GBG clients). If you’re an affiliate of Biocom California, BioUtah, Bio Nebraska, Focused Ultrasound Foundation, iBIO, Indiana Life Sciences Association, Georgia Life Sciences, IowaBio, MichBio, NCBiotech, NMBio, Ohio Life Sciences, South Dakota Biotech, VaBio, or BioWV – your membership gets you access to the [private consultation meeting](#).

JP Morgan Healthcare Conference – G2G Founder and CEO Liz Powell will be attending the conference in January. [Reach out](#) if you would like to connect with her there. If you are interested in attending the exclusive Women’s Health Advocates event on January 13 please fill out this [form](#).

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AGING (5)		
1.	Forecast: Complex Integrated Multi-Component Projects in Aging Research (U19 Clinical Trial Optional) (NIH/NIA) PAR-26-081	This NOFO will invite applications that propose large-scale, complex research projects with multiple highly integrated components focused on a common research question relevant to aging. Applications will involve a well-integrated research program composed of a multidisciplinary team of investigators within a single institution or a consortium of institutions. Applications will demonstrate how the individual components will be synergistically integrated to advance understanding of the unifying hypothesis or theme. https://www.grants.gov/search-results-detail/360911	TBD	Estimated post date: 3/25/26 Estimated proposal date: 5/25/26
2.	Forecast: Understanding Cerebellar Contributions to Cognitive and Affective Functions in Aging and Alzheimer's Disease/Alzheimer's Disease-Related Dementias (NIH/NIA) RFA-AG-26-018	This NOFO will solicit applications for research on the cerebellum’s contributions to cognitive and affective functions in healthy aging as well as in the context of AD/ADRD. This NOFO seeks studies to address the need for improved understanding of the physiology and neuroanatomy of the cerebellum in these processes in the context of healthy aging and AD/ADRD. This NOFO welcomes a mix of approaches including basic human and animal model studies, secondary data analyses of existing aging and AD/ADRD datasets, as well as studies examining the cerebellum as a potential target for interventions to promote cognitive reserve and/or prevent and delay the onset of AD/ADRD. https://www.grants.gov/search-results-detail/360894	TBD	Estimated post date: 8/6/26 Estimated proposal date: 10/6/26

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AGING		
3.	Forecast: Mechanisms Underlying Olfactory Dysfunction in Aging and Alzheimer's Disease and Alzheimer's Disease-Related Dementias (NIH/NIA) RFA-AG-26-021	This NOFO will solicit applications that investigate the mechanisms underlying the association between olfactory decline and aging or AD/ADRD. Understanding these mechanisms may help inform the potential use of olfactory dysfunction with age as an indicator of various health outcomes in older adults and as a predictor of AD/ADRD risk. Identifying circuit-level olfactory changes may also uncover novel targets for developing disease-modifying therapeutic strategies. https://www.grants.gov/search-results-detail/360893	TBD	Estimated post date: 8/6/26 Estimated proposal date: 10/6/26
4.	Forecast: Novel Approaches to Advance Precision Aging and Cognitive Health (NIH/NIA) RFA-AG-26-022	This NOFO will solicit applications that develop or incorporate novel, cutting-edge study designs/methods/analytic approaches through the use of machine learning, artificial intelligence, and adaptive designs to allow the discovery of health/function profiles at the level of the individual and that could lead to the implementation of personalized prevention plans/interventions for cognitive/brain health in older adults. The initiative would allow for both basic research in animal models, as well as the development of profiles for humans, which would span levels of analysis from cellular to societal. https://www.grants.gov/search-results-detail/360910	TBD	Estimated post date: 8/6/26 Estimated proposal date: 10/6/26
5.	Forecast: Renewal of NIA Research Centers Collaborative Network (RCCN) (NIH/NIA) RFA-AG-26-026	This NOFO will solicit applications to support the Research Centers Collaborative Network (RCCN). These collaborations are intended to leverage NIA's substantial investments by fostering and sustaining the development of novel interdisciplinary efforts in aging research. This renewal NOFO will call for continuation of the current high-value RCCN activities and encourage new activities, particularly among new and early stage investigators; expanded networking and collaboration tools; and development of enhanced mentoring infrastructure. https://www.grants.gov/search-results-detail/360876	TBD	Estimated post date: 3/1/26 Estimated proposal date: 5/25/26
		ARTIFICIAL INTELLIGENCE & MACHINE LEARNING (1)		
6.	Autonomous Interventions and Robotics (AIR) (ARPA-H) ARPA-H-SOL-26-146	The Autonomous Interventions and Robotics (AIR) program aims to catalyze the development of autonomous robotic surgery—an intervention during which a robot performs part, or all, of the procedure without direct human input. AIR encompasses two (2) technical areas: Technical Area 1 (TA1)—endovascular robotics, and Technical Area 2 (TA2)—microbots. Technical Area 1 comprises sub-areas TA1-A—endovascular robotic systems and TA1-B—endovascular simulation environment. https://sam.gov/opp/4175209961c549c28cce6595ee118272/view https://arpa-h.gov/explore-funding/programs/air	Dependent upon proposal	Proposers' Day: 12/16/25 Solution Summary: 1/26/26 Proposal: 3/30/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AUTOIMMUNE DISEASES (1)		
7.	Forecast: Autoimmune Diseases Statistical and Clinical Coordinating Center (AD-SCCC) (NIH/NIAID) RFA-AI-27-003	The AD-SCCC will provide clinical study development, support domestic and international regulatory requirements, site monitoring, repository management, manuscript production, study archiving, and biostatistical support for ongoing and future clinical trials in the areas of autoimmune diseases, mucosal immunology, and primary immune deficiencies. https://www.grants.gov/search-results-detail/360934	Total funding of \$8 million	Estimated post date: 3/6/26 Estimated proposal date: 6/4/26
		BIOMEDICAL RESEARCH (4)		
8.	Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional) (NIH) PAR-26-116	While translating basic research into clinical practice is increasingly difficult, time-consuming, and expensive, translational research is crucially important in converting basic scientific discoveries into new diagnostics and therapies for patients. As such, this NOFO intends to broaden and strengthen translational research collaborations between basic and clinical researchers both within and outside NIH to accelerate and enhance translational science. All teams must have at least one intramural and one extramural investigator. https://www.grants.gov/search-results-detail/359659	Up to \$500,000 per year, for up to 5 years	Multiple deadlines; NOFO open through 2/5/27
9.	Resource-Related Research Projects for Development of Models and Related Materials for Studying Human Health and Diseases (R24 Clinical Trials Not Allowed) (NIH/ORIP) RFA-OD-25-010	ORIP's intent with this NOFO is to support resource-related research projects that are aimed at developing and characterizing new human health- and disease-based resources, improving existing resources, or acquiring deep understanding of a model system to improve the utilization, accessibility, and translational value of experimental research models to the research community. https://www.grants.gov/search-results-detail/359648	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 9/28/28
10.	Animal and Biological Material Resource Centers (P40 Clinical Trial Not Allowed) (NIH/ORIP) RFA-OD-25-011	The goal of projects supported by this NOFO is to provide research resources that facilitate optimization and enhancement of scientific rigor, transparency, and experimental reproducibility of biomedical research. https://www.grants.gov/search-results-detail/359646	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 9/26/28
11.	Informatics, Coordination and Service Center for the Mutant Mouse Resource and Research Centers (U42 Clinical Trial Not Allowed) (NIH/ORIP) RFA-OD-25-012	The ICSC is expected to provide informatics and coordinating services to the MMRRRC consortium and biomedical researchers. Important functions of the ICSC are improvement, development, and maintenance of the Consortium's in-house data management systems in a format that may facilitate their integration with other animal and non-animal resource databases and community standards for information accessibility and interoperability. https://www.grants.gov/search-results-detail/359647	Up to \$650,000 per year, for up to 4 years	Multiple deadlines; NOFO open through 5/1/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOTECHNOLOGY AND BIOMANUFACTURING (1)		
12.	Forecast: Single Blood Donor Collection and Storage Bags Manufactured in Continental United States (CONUS) (MTEC) MTEC-26-01-BloodBag	In recent years, there has been a shortage of much needed blood storage bags, which is acute within the DoD system where there is a requirement for individually wrapped blood bags for use in far forward situations. The U.S. Government (USG) is looking for solutions to stand up CONUS manufacturing capabilities to ensure rapid scalable blood bag production in the event of need. https://mtec-sc.org/solicitations/pre-blood-bag	Up to \$3 million, for up to 1 year	TBD
		CANCER (6)		
13.	Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed) (NIH/NCI) PAR-26-091	This NOFO will solicit applications to support the validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. https://www.grants.gov/search-results-detail/360946	TBD	Estimated post date: 2/16/26 Estimated proposal date: 2/8/27
14.	Forecast: Metastasis Research Network (U54 Clinical Trial Not Allowed) (NIH/NCI) RFA-CA-25-031	This NOFO will solicit applications for research on developing a comprehensive and cohesive understanding of cancer metastasis. Each MetNet Center should propose an overarching scientific theme that will be pursued through two or three scientific inter- and multidisciplinary basic research projects. The projects should use integrative system level approaches to elucidate and integrate a mechanistic understanding of the non-linear, dynamic, and emergent processes in metastasis. https://www.grants.gov/search-results-detail/360881	Up to \$1.7 million	Estimated post date: 2/24/26 Estimated proposal date: 5/15/26
15.	Cancer Intervention and Surveillance Modeling Network (CISNET) (U01 Clinical Trial Not Allowed) (NIH/NCI) RFA-CA-25-032	This NOFO invites multiple PD/PI applications for collaborative research projects using simulation and other modeling techniques for specific cancer types (see below). The proposed research is expected to generate sophisticated, evidence-based tools capable of informing decisions on the most efficient utilization of existing and emerging technologies and strategies for the control of cancer. https://www.grants.gov/search-results-detail/360928	Up to \$1.24 million	Proposal: 2/11/26
16.	Forecast: Carcinogen Hazard Assessment Monographs Program (CHAMP) (R01 Clinical Trial Not Allowed) (NIH/NCI) RFA-CA-26-006	This NOFO will invite applications to critically and systematically evaluate the scientific evidence on carcinogenic hazards to humans. Identifying potential carcinogens is essential for guiding and advancing cancer research, as well as informing cancer control and prevention efforts. The resulting monographs will serve as crucial references that shape health policy and regulation, ultimately helping to reduce the cancer burden for all. https://www.grants.gov/search-results-detail/360905	TBD	Estimated post date: 2/14/26 Estimated proposal date: 6/30/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
17.	Using Real-World Data to Address Prevalence and Treatment of Cardiovascular, Kidney and Metabolic Disease in Cancer Patients and Survivors` (AHA)	<p>This RFP will fund research focused on the prevalence and treatment of cardiovascular, kidney and metabolic disease in cancer patients and survivors. A successful application will address one or more of the following topics: Defining the prevalence of cardiovascular, kidney, metabolic disease in cancer patients and survivors; Identifying how these patients are being treated; Identifying shared cardiometabolic risk factors between cancer and cardiovascular disease; Better understand cancers where cardiometabolic risk factors play a role in oncology outcomes, in particular obesity-related cancers; Design and implement randomized clinical trials investigating the effects of contemporary cardiometabolic interventions on cardiovascular and cancer outcomes; Use real world evidence to test if interventions that reduce cardiometabolic risk improve cardiovascular and cancer outcomes.</p> <p>https://professional.heart.org/en/research-programs/aha-funding-opportunities/cardiac-arrest-research-team-network</p>	\$150,000 for 1 year	Letter of intent: 1/19/26 Invited proposal: 3/26/26
18.	Partnering Research and Community Organizations for Comparative Clinical Effectiveness Research Across the Cancer Care Continuum PCORI Funding Announcement (The Cancer Partner PFA) – Cycle 1 2026 (PCORI)	<p>This PFA invites CER applications led by researcher-community partnerships that may focus on a range of research questions and decisional dilemmas relevant to the participating communities that address variations in care and outcomes across the cancer continuum. PCORI is particularly interested in submissions that address the following Special Areas of Emphasis: Addressing barriers to recommended cancer screening and timely follow-up in the general population and among individuals at high risk of cancer; Improving the delivery of patient-centered, evidence-based care during cancer treatment; and Addressing the post-treatment, follow-up care needs of cancer survivors.</p> <p>https://www.pcori.org/funding-opportunities/announcement/cancer-partner-pfa-cycle-1-2026</p>	Up to \$13 million, for up to 6 years	Letter of intent: 1/6/26 Proposal: 5/5/26
		ENDOCRINE & METABOLIC DISEASE (2)		
19.	Engineering Improved Stem Cell-Derived Islet Cells for Replacement Therapies (R01 - Clinical Trial Not Allowed) (NIH/NIDDK) RFA-DK-26-306	<p>This funding opportunity is designed to support research in understanding how to engineer intrinsic characteristics of stem cell-derived islet cell products that can result in improved cell replacement therapy outcomes. Unlike cadaveric human islets, stem cell-derived islet cell products are generated from well-defined and highly controlled cell bank sources. Their banking, manufacturing, and quality control processes can be used to instill optimized cell characteristics resulting in more resilient and durable graft viability and function. This funding opportunity aims to stimulate studies on targets and pathways amenable to such engineering approaches and to encourage preclinical testing and validation of such strategies.</p> <p>https://www.grants.gov/search-results-detail/360931</p>	Up to \$500,000	Proposal: 3/6/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ENDOCRINE & METABOLIC DISEASE		
20.	Diabetes Research Centers (P30 Clinical Trial Optional) (NIH/NIDDK) RFA-DK-26-310	This NOFO invites applications for Diabetes Research Centers (DRCs) that are designed to support and enhance the national research effort in diabetes, its complications, and related endocrine and metabolic diseases. The purpose of this Centers program is to bring together basic and clinical investigators to enhance communication, multidisciplinary collaboration, and effectiveness of ongoing research in Diabetes Research Center topic areas. https://www.grants.gov/search-results-detail/359145	Up to \$1.25 million per year, for up to 5 years	Multiple deadlines; NOFO open through 1/27/27
		FOOD ALLERGIES (3)		
21.	Food Allergy Fund Microbiome Collective (FAF)	Grants will be awarded to research teams that propose innovative approaches to understanding the role that the microbiome plays in the development and persistence of food allergy. We would welcome proposals identifying investigations into the interaction between the mucosal surfaces and the immune system that result in the development of allergic responses to food. We also would be interested in approaches that would interrupt this process and could be useful for the prevention or treatment of food induced allergy and anaphylaxis. https://foodallergyfund.org/funding-for-research#microbiome	Suggested funding tiers are \$75,000, \$150,000, and \$250,000	Letter of intent: 1/31/26
22.	Food Allergy Fund Drug Repurposing Program (FAF)	Grants will be awarded to research teams that propose innovative approaches to repurposing therapeutics for the prevention or treatment of food allergy. We would welcome proposals identifying either an existing FDA-approved drug or drug in development with human safety data that has a rationale for the prevention of food allergies, prevention or treatment of food induced anaphylaxis, or an improved method for maintaining food allergic tolerance in previously allergic patients. https://foodallergyfund.org/funding-for-research#drugrepurpose	Suggested funding tiers are \$75,000, \$150,000, and \$250,000	Letter of intent: 1/31/26
23.	Food Allergy Fund Innovators Research Grants (FAF)	On a rolling basis, FAF will award grants to the researcher or team of researchers who demonstrate the most innovative approach to identifying what causes food allergies or an improved treatment. https://foodallergyfund.org/funding-for-research#innovatorsgrant	Suggested funding tiers are \$75,000, \$150,000, and \$250,000	Letters of intent accepted on a rolling basis



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		GENOMICS (1)		
24.	Forecast: Illuminating AD/ADRD Genome to Enable Precision Genomic Medicine (NIH/NIA) RFA-AG-26-023	This NOFO will solicit applications that propose a program that supports integrative, cross-disciplinary projects aimed at scaling up mechanistic studies to understand the genomic underpinnings of the pathogenesis and progression AD/ADRD. The proposed research projects will employ interdisciplinary approaches that integrate innovative techniques to dissect the genomic drivers of AD/ADRD. These projects will leverage advanced analytical methods, including machine learning and comparative genomic analysis across multiple genetic ancestries or multiple neurodegenerative diseases, along with cutting-edge tools like genome editing, functional characterization assays, and emerging single-cell and spatial omics technologies. These studies will use sophisticated disease models, such as human stem cell-based systems, ex vivo, and in vivo models that reflect different genetic ancestries, various model organisms, or multiple neurodegenerative conditions. https://www.grants.gov/search-results-detail/360906	TBD	Estimated post date: 8/6/26 Estimated proposal date: 10/6/26
		HIV/AIDS (2)		
25.	Forecast: Centers for AIDS Research (CFAR) (NIH/NIAID) PAR-26-056	The national network of CFARs cooperates with other HHS-funded HIV/AIDS programs to establish and maintain the collaborations and infrastructure required to carry out innovative implementation science research for ending the HIV epidemic domestically. Addressing a complex chronic disease, HIV/AIDS research requires broad scientific expertise, access to unique biological samples, and cutting-edge research technologies that extend beyond the needs of individual research groups. The CFAR program strengthens HIV/AIDS research by providing infrastructure that fosters multidisciplinary collaborations, maximizes efficiencies by reducing duplication of efforts, and leverages economies of scale to facilitate the translation of basic research findings into new HIV treatment, prevention, and cure approaches. https://www.grants.gov/search-results-detail/360869	TBD	Estimated post date: 5/21/26 Estimated proposal date: 8/19/26
26.	Forecast: Implementation Science to End the HIV Epidemic (NIH/NIAID) RFA-AI-27-018	Projects will leverage research-community collaborations to bring evidence-based advances in HIV prevention, diagnosis, treatment, and cluster outbreak response to communities disproportionately impacted by HIV. The goals of these projects will be to: (1) Develop strategies to end HIV by integrating innovations across disciplines such as epidemiology, data science, public health, medicine, social services, implementation science, and community engagement, and (2) Deploy, test, and evaluate new or existing strategies at multiple geographic locations or settings. https://www.grants.gov/search-results-detail/360873	Total funding of \$7 million	Estimated post date: 2/13/26 Estimated proposal date: 4/17/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		IMMUNOLOGY & INFECTIOUS DISEASE (5)		
27.	Forecast: Infectious Diseases Clinical Trials Network (IDCTN) (NIH/NIAID) RFA-AI-27-002	The network, comprised of the Clinical Trial Evaluation Units (CTEUs) and a Network Coordination Center (NCC), supports the evaluation of therapeutics, vaccines, biologics, diagnostics, and devices targeting infectious diseases, including emerging and chronic infections. https://www.grants.gov/search-results-detail/360875	Total funding of \$29 million	Estimated post date: 3/13/26 Estimated proposal date: 6/11/26
28.	Forecast: Atopic Dermatitis Research Network – Clinical Research Centers (NIH/NIAID) RFA-AI-27-004	This program will support research centers across the United States conducting interdisciplinary and translational research to further improve our understanding of skin immunology and defense mechanisms by focusing on differences between individuals with atopic dermatitis and healthy controls in skin immune responses, structure, and function. https://www.grants.gov/search-results-detail/360874	Total funding of \$4.52 million	Estimated post date: 2/27/26 Estimated proposal date: 5/29/26
29.	Forecast: Coccidioidomycosis Collaborative Research Centers (NIH/NIAID) RFA-AI-27-012	The CCRCs are highly collaborative, multi-disciplinary, research centers that conduct clinical and translational research to support the development of a vaccine to combat coccidioidomycosis, a serious and difficult to treat fungal infection endemic in many regions of the United States. Activities to be supported align with the NIAID strategic plan for research to develop a Valley fever vaccine and include (1) addressing gaps in basic Coccidioides research, (2) development of tools and resources, and (3) development of a preventative vaccine. https://www.grants.gov/search-results-detail/360878	TBD	Estimated post date: 1/5/26 Estimated proposal date: 3/6/26
30.	Assay Development for Superior Understanding of Response and Efficacy (ASSURE) (BARDA/RRPV) RRPV 26-07-ASSURE	This program seeks to de-risk the development of novel assay platform technologies with the ultimate goal of establishing new, qualified assays primarily for BARDA and vaccine developers to comprehensively assess the immune response and status elicited by vaccines and/or infection due to CBRN threats, pandemic influenza, or other emerging infectious diseases. Some of these assays may lead to support of new correlates of protection. https://www.rrpv.org/uncategorized/assay-development-for-superior-understanding-of-response-and-efficacy-assure/	Dependent upon proposal and available funds	Proposal: 12/18/25
31.	RFI: New Vaccine Platforms (BARDA/RRPV)	The objective of this RFI is to solicit feedback from industry, academia, and other stakeholders to assist BARDA in identifying, and understand the development maturity of, vaccine platform technologies that (1) are safe and effective across a broad range of different known infectious disease threats and (2) can enable efficient development timelines in response to emerging infectious disease threats. https://www.rrpv.org/solicitation/request-for-information/new-vaccine-platforms/	N/A	Response: 1/9/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MATERNAL AND PEDIATRIC HEALTH (2)		
32.	Making Obstetric Care Smart (MOCS) (ARPA-H) ARPA-H-SOL-26-143	MOCS invites proposals across two technical areas: assigning risk scores for low fetal oxygen levels; and the development of novel, non-invasive, and wireless monitoring methods to assess that risk. The program expects teams to use new sensors paired with artificial intelligence and machine learning to predict infant status and provide the best recommendations for intervention. https://sam.gov/workspace/contract/opp/78d39e1b728d4f80b312f760db09c646/view https://arpa-h.gov/explore-funding/programs/mocs	Dependent upon proposal	Pre-proposal discussions: 12/15-12/19/25 Proposal: 1/21/26
33.	Forecast: Pediatric and Reproductive Environmental Health Scholars (PREHS) Program (NIH) RFA-ES-26-004	The goal of the PREHS program is to create a strong network of healthcare professionals who possess the skills and knowledge to address the complexities of pediatric and reproductive environmental health. The PREHS program will introduce new pediatric healthcare providers, obstetricians and gynecologists, and other healthcare professionals with state of the art environmental health training that blends academic research and practice-based applications in real-world settings. https://www.grants.gov/search-results-detail/360926	TBD	Estimated post date: 3/23/26 Estimated proposal date: 5/23/26
		PATIENT-CENTERED RESEARCH (1)		
34.	Improving Health Decision Making With Comparative Clinical Effectiveness Research: Retrospective Observational Studies Leveraging Existing Data Sources PCORI Funding Announcement -- Cycle 1 2026 (PCORI)	This PFA seeks to fund well-designed, retrospective observational studies that articulate a clear comparative effectiveness question by leveraging established data sources and infrastructure ready for patient-centered CER, including but not limited to PCORnet®, the National Patient-Centered Clinical Research Network. Given the retrospective observational nature of this PFA, applications are expected to compare existing interventions that represent a current decisional dilemma and have robust evidence of efficacy or are currently in widespread use. Clinical interventions and delivery system interventions are appropriate for these studies. All applications must address one of the Topic Themes . https://www.pcori.org/funding-opportunities/announcement/improving-health-decision-making-observational-comparative-clinical-effectiveness-research	Up to \$2 million, for up to 18 months	Letter of intent: 1/6/26 Proposal: 5/5/26
		REGULATORY SCIENCE (1)		
35.	FY26 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science (FDA) FDABAA-26-00123	The FDA anticipates that research and development activities awarded under this BAA will serve to advance scientific knowledge to accomplish its mission to protect and promote the health of our nation. There are three charges: Charge I: Modernize development and evaluation of FDA-regulated products; Charge II: Strengthen post-market surveillance and labeling of FDA-regulated products; and Charge III: Invigorate public health preparedness and response of the FDA, patients, and consumers. https://sam.gov/workspace/contract/opp/803a5109fa3c49ebae21c22167a9a8d4/view	Dependent upon proposal and award mechanism	Proposal: 2/24/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		THERAPEUTICS (2)		
36.	Evidence-Based Validation & Innovation for Rapid Therapeutics in Behavioral Health (EVIDENT) (ARPA-H) ARPA-H-CXHUB-26-109 ARPA-H-CXHUB-26-110	EVIDENT aims to catalyze a new era in behavioral health by generating and validating objective FDA-ready clinical endpoints for emerging therapies, enabling rapid, personalized, and durable improvements in mental and behavioral health. There are four Technical Areas, three under the Exploratory NOFO and one under the Rolling NOFO. Technical Area 1: Objective Measurement of Clinical Change; Technical Area 2: Mechanisms of Rapid, In-Session Change; Technical Area 3: Personal Risk and Durability Profiles; and Technical Area 4: Collection of Supplemental Data & Biological Samples in Existing Clinical Trials. https://www.customerexperiencehub.org/evident/	\$4 million, for up to 2 years (TA1-3) \$10 million, for up to 2 years (TA4)	Proposers' Day: 12/10/25 Solution Summary: 12/22/25 (TA1-3) Proposals accepted on a rolling basis until funds are expended (TA4)
37.	BioStabilization Systems (BoSS) (ARPA-H) ARPA-H-SOL-26-136	The BoSS program aims to make the seemingly impossible problem of room temperature biologics possible by pioneering new technologies to produce, store, and ship cells at room temperature, without any need for refrigeration. The program will eliminate deep freeze requirements, paving the way for a new era of efficient and resilient manufacturing and distribution of biologic drugs. BoSS will take inspiration from nature to revolutionize preservation technology. The program has two technical areas: 1) development of cell interventions to enable stabilization and restoration and 2) engineering of scalable cell processing systems that can deploy biostabilization strategies. https://sam.gov/workspace/contract/opp/aadd5b36db484e0a8f4e29d77af9f081/view https://sam.gov/workspace/contract/opp/7bb27fb4f4ae48598bc3dac6a297ea88/view	Dependent upon proposal and award mechanism	Proposers' Day: 1/29/26 Solution Summary: 2/19/26 Solution Pitch: 3/26/26
		WOMEN'S HEALTH (1)		
38.	Redefining Women's Health: From Heart to Head to Hormones (AHA)	Despite significant progress in biomedical research, many conditions that disproportionately, differently, or distinctly impact women remain underdiagnosed, undertreated, and underfunded. This call focuses on four priority areas where transformative science and innovation are urgently needed: Ischemia with Non-Obstructive Coronary Arteries (INOCA) and Cardiovascular Microvascular Disease (CMD); Autoimmune Disease Screening, Predictors, and Care Models; Next-Generation Treatments for Endometriosis; and Classification and Care Models for Heavy Menstrual Bleeding (HMB). Only proposals with a feasible path for implementation, scalability and potential commercialization will be considered. Awards will be made only to eligible nonprofit institutions; however, inclusion of subcontracted industry partners who have expertise in key areas of the proposed studies is encouraged. https://professional.heart.org/en/research-programs/aha-funding-opportunities/redefining-womens-health-from-heart-to-head-to-hormones	\$100,000 for 1 year	Pre-proposal: 1/6/26 Invited proposal: 4/14/26



Recurring Opportunities

December 9, 2025

<https://www.g2gconsulting.com/gbg-reporting-service/>

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (4)		
39.	Resilient Systems Office (RSO) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-103	RSO is interested in innovations that take a systems level approach in areas including, but not limited to, systems biology, data systems, biophysical systems, health IT systems, sociotechnical systems, health-related systems engineering, and other systems with the potential to improve health outcomes. https://sam.gov/workspace/contract/opp/36eb58892e1f49f897c81d87ff7a95fe/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29
40.	Health Science Futures (HSF) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-104	HSF awardees will develop innovative technologies, tools, and platforms that can be applied to a broad range of diseases. The following interest areas define the ground-breaking research we seek to support: Breakthrough Technologies; Transformative Tools; and Platform Systems. https://sam.gov/workspace/contract/opp/29c3ac2ea6754d1f897f9c71204c0eea/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29
41.	Scalable Solutions Office (SSO) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-105	ARPA-H SSO seeks solutions to improve the scalability and affordability of health care solutions, bridge gaps in underserved areas, and extend remote access to expertise by developing location-specific interventions, telemedicine solutions, and mobile health clinics. Solutions should focus on rapid innovation and the use of partnerships, also flexible distribution networks and streamlined manufacturing processes. SSO interest areas include: Advanced Technologies for Medical Product and Capability Distribution; and Biomanufacturing Innovations. https://sam.gov/workspace/contract/opp/c79dfo57a7e44d2cb3072e4ce3307422/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29
42.	Proactive Health Office (PHO) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-106	The Proactive Health Office (PHO) at ARPA-H is seeking solutions to improve the healthspan and health outcomes of Americans prior to the onset of disease and/or the development of diminished quality of life from illness. Interest areas include: Novel prevention, detection and prophylactic treatment methods for disease; Population-level approaches to increase the adoption of prevention and wellness behaviors; and System innovation for the delivery of proactive health outcomes. https://sam.gov/workspace/contract/opp/a5b72db5139040f8b2a1dcc2d2c96733/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AIR FORCE (4)		
43.	Continuing Human Enabling, Enhancing, Restoring and Sustaining (CHEERS) FA238424S2233	CHEERS MAA is intended to provide a comprehensive strategy for AFRL/RH and USAFSAM's range of S&T, allowing for progression from basic research to technology maturation and transition. Areas of interest include: Aerospace Medicine and Physiology; Public Health and Preventative Medicine; Occupational Medicine and Bioenvironmental Engineering; and En Route Care/Expeditionary Medicine/Prolonged Field Care. https://sam.gov/opp/4caa8d320fb24050b389fe721296a13d/view	Dependent upon proposal and award mechanism	White papers accepted on a rolling basis
44.	AFRL/RX Functional Materials Open BAA FA8650-22-S-5002	The Functional Material Open BAA seeks to exploit innovative functional materials that enable new warfighting capabilities, significantly improve the effectiveness of warfighters and their current and future systems and solve urgent operational needs. The Biomaterials Materials and Processes (BM&P) Research area seeks to accelerate materials development, protect assets from the environment, and enable airman performance. This research area harnesses materials and processes competencies in soft matter materials characterization, molecular and synthetic biology, microbiology, biochemistry, bioinformatics, machine learning, multiscale modeling, bioelectronics, bio- functionalization, and biological engineering to create materials not easily achievable through traditional chemical synthesis or additive manufacturing. https://sam.gov/opp/2fadbd41c2700409c993a8c308c6f5120/view	Dependent upon proposal and award mechanism	White paper: 10/28/28
45.	Research Interests of the Air Force Office of Scientific Research FA9550-25-S-0001	The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. The Chemistry and Biological Sciences Team is responsible for research activities in chemistry and biological sciences. The focus is on complex materials, microsystems and structures and well as systems of a biological nature by incorporating hierarchical design of mechanical and functional properties from the nanoscale through the mesoscale, ultimately leading to controlled well- understood chemistry/biochemistry, and material or structural behavior capable of dynamic functionality and/or performance characteristics to enhance mission versatility. https://www.grants.gov/search-results-detail/359050	Dependent upon proposal, for up to 5 years	White papers accepted on a rolling basis
46.	Research Interests of the United States Air Force Academy USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions. https://www.grants.gov/search-results-detail/330175	Dependent upon proposal, for up to 5 years	Proposals accepted on a rolling basis



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY (9)		
47.	The Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense Broad Other Transaction Authority Announcement (BOTAA) BOTAA-24-01	JPEO-CBRND is interested in efforts directed toward the development of enabling technologies that speed up the advanced development process. Areas of interest include: Software and Artificial Intelligence (AI), wearable sensors, threat detection, biothreat containment and aeromedical evaluation. https://sam.gov/opp/2d04622b25364669857a6a61c576ade9/view	Dependent upon proposal	Preproposals accepted through 2/7/29
48.	BAA R&D in Support of the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB CBRND-BAA-22-01	The JPMO is interested in studies on new and better ways to develop medical CBRN countermeasures more rapidly and with increased efficiency through enabling technologies, life cycle bioinformatics, and improved logistics tracking. Mission areas include: Biological Medical Prophylaxis; Medical, Chemical, and Biological Countermeasures; Medical Radiological Countermeasures; Medical Diagnostic and Surveillance Systems; and Enabling Biotechnologies and Response Systems. https://sam.gov/opp/f2d01f5a6c444e32af543e9519a0805f/view	Dependent upon proposal	Proposals accepted on a rolling basis through 6/11/27
49.	USAMRDC Broad Agency Announcement for Extramural Medical Research HT9425-23-S-BAA1	R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease; Combat Casualty Care; and Military Operational Medicine. https://www.grants.gov/search-results-detail/343725	Dependent upon proposal, for up to 5 years	Pre-applications accepted until 9/30/27 Full proposal by invitation
50.	USSOCOM BAA for Extramural Biomedical and Human Performance Research and Development HT9425-23-S-SOC1	A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel for early intervention in life-threatening injuries; PFC; human performance optimization; canine medicine/performance; brain health; immune response; automation of systematic reviews and metanalysis; and novel post-traumatic stress, depression, and anxiety treatment. SOF medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. https://www.grants.gov/search-results-detail/349586	Dependent upon proposal	Proposals accepted through 7/31/28 Submission of a pre-proposal is required
51.	Army Research Office Laboratory Broad Agency Announcement for Foundational Research W911NF-23-S-0001	ARL's foundational research mission spans basic research and applied research but may include advanced technology development and advanced component development and prototypes when opportunities arise to directly or indirectly help achieve ARL's mission. Topics include Biotronics, Genetics, and Neurophysiology of Cognition; the full list of research topics is available . https://sam.gov/opp/7560e5d4024b4e94ad3eab6180cfcc36/view	Dependent upon proposal	Proposals accepted on a rolling basis until 11/20/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY		
52.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic, Applied, and Advanced Research W911NF-23-S-0010	ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology. https://sam.gov/opp/ee8d9eeec4f94269b6e1ac16b09d9417/view	Dependent upon proposal	Proposals accepted on a rolling basis until 4/30/28 Full proposal required
53.	Army Applications Lab BAA for Disruptive Applications W911NF-24-S-0008	AAL is seeking technologies that address a wide range of Army needs consistent with CFT capability focus areas and associated programs and lines of effort as well as potentially disruptive new capabilities that augment or enhance Army capability overmatch. https://sam.gov/opp/3f8ec6d36d584ca28364a2f8a10255b7/view	Dependent upon proposal	Proposals accepted through 4/4/29 Pre-proposal is required
54.	Basic and Applied Research at the US Army Combat Capabilities Development Command - Soldier Center W911QY-25-R-0023	The Soldier Center is seeking solutions in the following scientific and technical areas: Combat Feeding & Equipment; Soldier Protection & Survivability; Modeling & Simulation; Human Performance & Biomechanics; Expeditionary Maneuver Support; Aerial Delivery; and Simulation & Training Technology. https://sam.gov/opp/e85e373d22ef47018b0336fc6a258002/view	Dependent upon proposal	Concept papers accepted on a rolling basis until 2/27/30
55.	Medical CDID BAA MED CDID	MED CDID invites innovative proposals that allow future Army medical units to efficiently and effectively clear the battlefield (evacuation of wounded, ill, and injured), maximize return to duty, and overcome contested logistics (medical resupply). https://vulcan-sof.com/login/ng2/submission?collectionUuid=5417cc3c-2b60-446a-addf-c0bea38cd0b1	Dependent upon proposal	White papers accepted through 12/31/2030
56.	BAA for Chemical, Biological, Radiological, Nuclear, and Explosive Defense Efforts W911SR-24-R-DEVB	DEVCOM CBC's mission is to provide innovative chemical, biological, radiological, nuclear and explosive (CBRNE) defense capabilities to enable the Joint Warfighters' dominance on the battlefield and interagency defense of the homeland. Mission areas include: Sensor technologies and biomaterials; Biological point detection; Chemical point detection; Early warning and detection; Collective protection; Respiratory protection; Decontamination; CBRN countermeasures; and Chemical biological advanced materials and manufacturing science. https://sam.gov/opp/fca6a4b42ff94fd5892fdae9799941f/view	Dependent upon proposal and award mechanism	Preproposals accepted through 8/20/29



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<u>BARDA (2)</u>		
57.	BARDA Broad Agency Announcement BAA-23-100-SOL-00004	BARDA is accepting proposals related to diagnostics and POC tests for COVID and other MCM topics that include: CBRN Vaccines, Antivirals & Antitoxins; Antimicrobials; Radiological/Nuclear MCMs; Chemical Threat MCMs; Burn and Blast Medical MCMs; Diagnostics; Influenza & Emerging Diseases vaccines and therapeutics; ImmuneChip+; Flexible and Strategic Therapeutics (FASTx). https://sam.gov/opp/d832248e72e14c3c8cee96ee3c8b2170/view	Dependent upon proposal	Proposal: 9/25/28
58.	BARDA DRIVe EZ-BAA DRIVeEZBAA22100SOL00003	All AOIs are currently closed. No initial awards will be executed. Eligible +Phase submissions will still be accepted and reviewed in accordance the process outlined the EZBAA and corresponding AOI. https://sam.gov/opp/6684d4a2734047d58d6cbf7e50bdd00a/view	Up to \$750,000 per award	Proposals accepted on a rolling basis Deadlines vary by AOI
		<u>DARPA (3)</u>		
59.	Expedited Research Innovation System (ERIS) DARPA-PS-25-05	DARPA seeks to obtain solutions or capabilities that deliver breakthrough technological advancements that are new as of the date of submission; or technologies, processes, research or methods. Topics include: Advanced technologies for defense against potential chemical and biological threats; Advanced technologies for the improved resilience of US operations throughout the prepare, deployment, execute, and return cycle; and Development of groundbreaking methods and metrology for complex, emergent, and adaptive systems, going beyond the limitations of current reductive scientific methods. https://sam.gov/workspace/contract/opp/fabda3a3d150457d97068977672ec750/view	Dependent upon proposal and award mechanism	Proposal: 5/30/26
60.	Biological Technologies BAA HR001124S0034	Research in BTO creates biotechnological capabilities that provide tactical care and restore function to injured warfighters, increase operational resilience, develop novel functional materials, and detect and protect against threats to maintain force readiness. BTO is interested in submissions related to the following topic areas: AI/ML; Combat Casualty Care; Human Performance; Materials, Sensors, Processing; Agricultural and Environmental; Security, Safety, and Surveillance; and Biomedical and Biodefense. https://sam.gov/workspace/contract/opp/8d403582edfd409795560247e8d229b7/view	Dependent upon proposal	Abstracts & proposals accepted on a rolling basis until 9/30/26
61.	Defense Sciences Office, Office-wide HR001125S0013	The DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: Materials, Manufacturing, & Structures; Sensing and Measurement; Math, Computation, and Processing; Complex, Dynamic, and Intelligent Systems. https://sam.gov/opp/c3f0bedbf22c4e2daf5bbo7a13f4ce4a/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 6/2/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DEFENSE THREAT REDUCTION AGENCY (4)		
62.	Research and Development Innovations Broad Agency Announcement HDTRA1-22-S-0003	DTRA seeks proposals that will advance research, development, test, and evaluation (RDT&E) priorities across five interrelated thrust areas derived from the 2022 DTRA Strategic Plan for RDT&E : <ul style="list-style-type: none"> • Understand current and emerging WMD situations, threats, and capabilities • Enable effective and integrated WMD deterrence • Control, disable, and defeat current and emerging WMD threats • Protect the force and mitigate crises from WMD • Enable cross-cutting capabilities https://sam.gov/workspace/contract/opp/d5bcd60592c84adf908c5c1ca747bc4e/view	Dependent upon proposal, for up to 18 months	White papers accepted on a rolling basis through 2/14/27
63.	Biological Threat Reduction with Global Partners Broad Agency Announcement (BAA) HDTRA1-24-S-0002	BTRP supports international health security efforts to address diseases caused by U.S. Biological Select Agents, pathogens of pandemic potential, and emerging infectious diseases. BTRP achieves its mission through collaboration with partner countries and the international community to minimize the threat of deliberate, accidental, and natural infectious disease outbreaks through enhanced detection, diagnosis, and reporting capabilities and biosecurity and biosafety measures. https://www.grants.gov/search-results-detail/353860	Dependent upon proposal and award mechanism	Proposal: 4/28/29
64.	FY25-29 Strategic Trends Research Initiative Broad Agency Announcement HDTRA1-24-S-0003	SI-ST's research explores a range of challenges related to nuclear, chemical, and biological weapons. The three WMD-relevant Research Thrust Areas are: strategic international dialogues, analytical studies, and emerging CWMD researcher projects. An area of general interest is: Future trends related to biological warfare, biodefense, biosecurity, and bio preparedness. https://sam.gov/opp/7a98bf70ac2a49c8b8eod71abbc93750/view	Dependent upon proposal and award mechanism`	White papers accepted on a rolling basis through 8/1/29
65.	Fundamental Research to Counter Weapons of Mass Destruction (C-WMD) HDTRA1-25-S-0001	Fundamental research efforts enable capabilities such as development of improved detection devices for traditional and nontraditional chemical agents; development of diagnostics for existing and emerging infectious disease threats; increasing knowledge and improved capabilities for development of new or improved medical and material countermeasures to CB threats for both pre- and post-exposure scenarios; enhanced personal protection against, modeling of, prevention of, or decontamination of CB threats; and providing effective elimination strategies via non-kinetic approaches for threat agent destruction, neutralization and/or sequestration. https://www.grants.gov/search-results-detail/356612	Up to \$1 million per year, for up to 5 years	White papers accepted through 9/2034



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DEPARTMENT OF ENERGY (1)		
66.	FY 2026 Continuation of Solicitation for the Office of Science Financial Assistance Program DE-FOA-0003600	SC accomplishes its mission and advances national goals by supporting: The frontiers of science—exploring nature’s mysteries from the study of fundamental subatomic particles, atoms, and molecules that are the building blocks of the materials of our universe and everything in it to the DNA, proteins, and cells that are the building blocks of life. Each of the programs in SC supports research probing the most fundamental disciplinary questions. https://www.grants.gov/search-results-detail/360678	Dependent upon award mechanism	Proposals accepted on a rolling basis through 9/30/26
		NAVY (2)		
67.	FY25 Long Range Broad Agency Announcement for Navy and Marine Corps Science and Technology N0001425SB001	The ONR, ONR Global, and Marine Corps Warfighting Lab are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. https://sam.gov/workspace/contract/opp/oefe2fde0926428f8ecc073fc7b5d9/view	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/26
68.	NRL Long Range Broad Agency Announcement (BAA) for Basic and Applied Research N00173-24-S-BA01	The Naval Research Laboratory is seeking to advance technology developed for in vitro diagnostic devices that are amenable to military hardening and integration with communication capabilities to support the medical diagnostic and epidemiological detection and biosurveillance needs of the US military across multiple Echelons of Care and specifically for field deployment at Echelons 1 or 2. https://sam.gov/workspace/contract/opp/f85a428ac9ac46c4a3278e11394c18d9/view	Dependent upon proposal and award mechanism	White papers accepted through 3/31/26
		OFFICE OF THE UNDERSECRETARY OF DEFENSE		
69.	OUSD(R&E) Seeks Advanced Manufacturing, Prototypes and Materials (AMPAM) HQ003425BOTA1	OUSD(R&E)’s goal is to foster increased collaboration and partnership between Government and Industry to identify, develop, and mature new or improved manufacturing and repair processes and bridge the gap between discovery and implementation of new capabilities for the warfighter. Examples may include Bio-manufacturing of medical related material and Bio-manufacturing of materials or products in the supply chain. https://sam.gov/opp/64a31b87112843b58dfb13f37bfa3df1/view	Dependent upon proposal and award mechanism	White papers accepted on a rolling basis through 10/2/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE (4)		
70.	Phased Large Awards for Comparative Effectiveness Research -- Cycle 1 2026	PCORI is interested in research that aims to fill pertinent evidence gaps representing decisional dilemmas for patients, caregivers, clinicians, policymakers and other healthcare system stakeholders, with a goal of generating evidence that helps patients and members of the broader health and healthcare community make informed decisions about their health care and health outcomes. Applicants to the Cycle 1 2026 PLACER PFA may select up to three Topic Themes ; or Other. https://www.pcori.org/funding-opportunities/announcement/phased-large-awards-comparative-effectiveness-research-pcori-funding-announcement-cycle-1-2026	Up to \$22 million, for up to 6.5 years	Letter of intent: 1/6/26 Proposal: 5/5/26
71.	Broad Pragmatic Studies Funding Announcement -- Cycle 1 2026	PCORI seeks to fund patient-centered CER comparing two or more alternatives, each of which has established efficacy and/or is in widespread use. PCORI is interested in research that fills pertinent evidence gaps representing decisional dilemmas for patients, caregivers, clinicians, policymakers and other healthcare system stakeholders, with a goal of generating evidence that helps patients and members of the broader healthcare community make informed decisions about their health care and health outcomes. Applicants for the 2026 BPS PFA may select up to three of PCORI's Topic Themes ; or "Other." Cycle 1 SAEs include: Addressing Obesity; Treatments and Strategies To Address Menopausal Symptoms; and Improving Care Delivery for Individuals With Intellectual and Developmental Disabilities (IDD). https://www.pcori.org/funding-opportunities/announcement/broad-pragmatic-studies-pcori-funding-announcement-cycle-1-2026	Up to \$12 million, for up to 5 years Dependent upon award mechanism Dependent upon award mechanism	Letter of intent: 1/6/26 Proposal: 5/5/26
72.	Advancing the Science of Engagement in Research PCORI Funding Announcement -- Cycle 1 2025	This PFA will fund studies that build an evidence base on engagement in research, including: Measures to capture structure/context, process, and outcomes of engagement in research; Techniques that lead to effective engagement in research; and How effective engagement techniques should be modified and resourced for different contexts, settings, and communities. It will solicit applications that focus on: Development and validation of measures to capture structure/context, process and outcomes of engagement, for both stakeholders and investigators; and Development and/or testing of engagement methods to generate evidence on the most effective approaches for engagement in research and how effectiveness varies by context. https://www.pcori.org/funding-opportunities/announcement/advancing-science-engagement-research-pcori-funding-announcement-cycle-1-2026	Up to \$1.5 million, for up to 3 years	Letter of intent: 1/6/26 Proposal: 5/5/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE		
73.	Improving Methods for Conducting Patient-Centered Comparative Clinical Effectiveness Research PCORI Funding Announcement -- Cycle 1 2026	<p>PCORI seeks to fund projects that address important methodological gaps and lead to improvements in the strength and quality of evidence generated by CER studies. For this PFA, PCORI has identified the following areas as programmatic priorities: Methods to Improve the Use of AI and ML in CER; Methods to Improve Study Design; Methods to Support Data Research Networks; Methods Related to Ethical and Human Subjects Protections Issues in CER.</p> <p>https://www.pcori.org/funding-opportunities/announcement/improving-methods-conducting-patient-centered-comparative-clinical-effectiveness-research-pcori-funding-announcement-cycle-1-2026</p>	Up to \$750,000, for up to 3 years	<p>Letter of intent: 1/6/26 Proposal: 5/5/26</p>





Terms

AoI: Area of Interest
BAA: Broad Agency Announcement
FOA: Funding Opportunity Announcement
IC: NIH Institutes and Centers
NOFO: Notice of Funding Opportunity
NOSI: Notice of Special Interest
PI: Principal Investigator
RFI: Request for Information
RFP: Request for Proposal
SBIR: Small Business Innovation Research
SDOH: Social Determinants of Health
STTR: Small Business Technology Transfer
TRL: Technology Readiness Level

Agencies

ARPA-H: Advanced Research Projects Agency for Health
ASPR: Administration for Strategic Preparedness and Response
BARDA: Biomedical Advanced Research and Development Authority
CDC: Centers for Disease Control and Prevention
CDMRP: Congressionally Directed Medical Research Programs
DARPA: Defense Advanced Research Projects Agency
DHA: Defense Health Agency
DoD: Department of Defense
FDA: U.S. Food and Drug Administration
MTEC: Medical Technology Enterprise Consortium
NIH: National Institutes of Health
NSF: National Science Foundation
PCORI: Patient-Centered Outcomes Research Institute
USAMRDC: U.S. Army Medical Research and Development Command
USAMRIID: U.S. Army Medical Research Institute of Infectious Diseases
USSOCOM: United States Special Operations Command

GBG Acronyms

Updated Monthly

December 9, 2025

<https://www.g2gconsulting.com/gbg-reporting-service/>

NIH Institutes and Centers

CC: NIH Clinical Center
CIT: NIH Center for Information Technology
CSR: NIH Center for Scientific Review
FIC: Fogarty International Center
NCATS: National Center for Advancing Translational Sciences
NCCIH: National Center for Complementary and Integrative Health
NCI: National Cancer Institute
NEI: National Eye Institute
NHGRI: National Human Genome Research Institute
NHLBI: National Heart, Lung, and Blood Institute
NIA: National Institute on Aging
NIAAA: National Institute on Alcohol Abuse and Alcoholism
NIAID: National Institute of Allergy and Infectious Diseases
NIAMS: National Institute of Arthritis & Musculoskeletal & Skin Diseases
NIBIB: National Institute of Biomedical Imaging and Bioengineering
NICHD: Eunice Kennedy Shriver National Institute of Child Health and Human Development
NIDA: National Institute on Drug Abuse
NIDCD: National Institute on Deafness and Other Communication Disorders
NIDCR: National Institute of Dental and Craniofacial Research
NIDDK: National Institute of Diabetes and Digestive and Kidney Diseases
NIEHS: National Institute of Environmental Health Sciences
NIGMS: National Institute of General Medical Sciences
NIMH: National Institute of Mental Health
NIMHD: National Institute on Minority Health and Health Disparities
NINDS: National Institute of Neurological Disorders and Stroke
NINR: National Institute of Nursing Research
NLM: National Library of Medicine

Join the private GBG Zoom Meeting:

<https://uso6web.zoom.us/j/89980906104?pwd=Mot984oYbUzyW82OnPIV7bTe2s82Ya.1>

Meeting ID: 899 8090 6104

Passcode: 810104

